DETERMINE TIME TO DEVELOPMENT OF AIDS DEFINING COMPLICATIONS & INFECTIONS

确定艾滋病定义并发症的发展时间

• 批准号: 7375194
• 负责人: THOMAS C MERIGAN
• 金额: $ 1.33万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375194
• 关键词: DETERMINE; TIME; DEVELOPMENT; AIDS; DEFINING

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Determine the overall rates of and risk factors for AIDS-defining complications and serious bacterial infections in subjects in the parent study, ACTG 362. Secondary 1. Determine the overall rates and risk factors (e.g. triglycerides, cholesterol, waist-to-hip ratio) for the development of cardiovascular disease in the study cohort. Cardiovascular events of interest include: myocardial infarction, coronary artery revascularization procedures, angina, sudden cardiac death, and stroke. 2. Compare the time to development of AIDS-defining complications and serious infections or cardiovascular disease in subjects who were assigned to receive Azithromycin to those who were assigned to receive placebo. 3. Evaluate the association between CD4 counts and HIV RNA levels at baseline and during follow-up and risk of opportunistic infections and other HIV-related complications. 4. Compare mortality in subjects who were assigned to receive Azithromycin to those who were assigned to receive placebo. 5. Define the risk of cognitive deterioration in a cohort of patients who have been severely immunosuppressed and recovered CD4 counts while taking Highly Active Antiretroviral Therapy (HAART). 6. Identify immunologic (CD4 counts) and virologic (plasma HIV RNA levels) markers and specific drugs (especially PIs) associated with cognitive decline. 7. Evaluate factors associated with long-term adherence to antiretroviral medications and the effect of adherence on viral suppression over time and on the development of opportunistic and serious bacterial infections and cardiovascular disease.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。主要确定母研究ACTG 362受试者中AIDS定义并发症和严重细菌感染的总体发生率和风险因素。 中一。 确定研究队列中发生心血管疾病的总体发生率和风险因素（例如甘油三酯、胆固醇、腰臀比）。关注的心血管事件包括：心肌梗死、冠状动脉血运重建术、心绞痛、心源性猝死和卒中。2.比较接受阿奇霉素和接受安慰剂治疗的受试者发生AIDS定义的并发症和严重感染或心血管疾病的时间。3. 评估基线和随访期间CD 4计数和HIV RNA水平与机会性感染和其他HIV相关并发症风险之间的相关性。4. 比较接受阿奇霉素治疗和接受安慰剂治疗的受试者的死亡率。5.定义在接受高效抗逆转录病毒治疗（HAART）期间严重免疫抑制和CD 4计数恢复的患者队列中认知恶化的风险。6. 识别与认知能力下降相关的免疫学（CD 4计数）和病毒学（血浆HIV RNA水平）标志物以及特定药物（尤其是PI）。7. 评价与长期坚持抗逆转录病毒药物治疗相关的因素，以及随着时间的推移，坚持抗逆转录病毒药物治疗对病毒抑制的影响，以及对机会性和严重细菌感染和心血管疾病的影响。